what a week
That was arguably the best conference call I have listened to this company host in the 16 years I have been a shareholder. The information, pictures , logic and numbers were compelling...even staggering. I really didnt see such a meaningful positive development coming .
I think the market is only beginning to truly digest and appreciate what this Diabetes wound treatment angle means to Prometic. If you dare to extrapolate that there are likely at least a couple other chronic wound treatment indications that are patentable for Pg, it all gets kinda silly. Layer in Pierres comment about the upcoming initial Human Efficacy / Biomarker data for 4050, and its almost like we just got a huge insurance policy.
Undoubtedly Pierre and crew have seen some of the human 4050 efficacy data. We all have hoped for over a year that the incredible animal model data would translate to humans. Yet almost every analyst has attributed a 80-90% discount to 4050 in their models.
Would Pierre honestly say, " you dont want to miss that date " on the conference call in reference to the 4050 data if the data wasnt positive / impressive ?
IF IT IS, every coverage analyst will be re-writing their valuation models meaningfully upward. In combination with the fact that the market is still way behind the curve on the Pg, we arent even out of the 3rd inning yet. Not selling a single share